Supplements
The Practitioner's Guide to What Supplements Affect Lp(a)?
Lipoprotein(a) — or Lp(a) — is one of the most underdiagnosed cardiovascular risk factors in clinical practice, yet roughly 1 in 5 people carry levels high enough to meaningfully raise their risk of heart attack and stroke. Unlike LDL, Lp(a) is predominantly determined by genetics, which makes it stubbornly resistant to lifestyle changes alone. Understanding which supplements can actually move the needle — and which are overhyped — is essential for anyone serious about long-term cardiovascular health.
Why Lp(a) Is the Cardiovascular Marker Most Doctors Still Miss
Lipoprotein(a), or Lp(a), is a modified form of LDL cholesterol with an additional protein called apolipoprotein(a) attached. This structure makes it particularly atherogenic: it promotes plaque formation, inhibits fibrinolysis, and triggers vascular inflammation through mechanisms distinct from standard LDL. The American Heart Association has flagged Lp(a) as an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD), with genetic studies from large-scale Mendelian randomization analyses confirming that each 50 nmol/L increase in Lp(a) raises ASCVD risk significantly (Kamstrup et al., Journal of the American College of Cardiology, 2013; PMID: 23583241).
Yet routine lipid panels don't measure it. Most patients go decades without ever knowing their Lp(a) level. And when elevated Lp(a) is finally identified — often after a cardiac event — clinicians and patients alike are left wondering: what can actually be done?
The honest answer is nuanced. Statins, the cornerstone of lipid management, have little to no effect on Lp(a) — and some data suggest they may modestly raise it. Emerging pharmaceutical agents like PCSK9 inhibitors and RNA-targeted therapies show promise for Lp(a) specifically, but access and cost remain barriers. That leaves a growing body of supplement and nutritional research that's worth examining carefully.
This guide covers what the peer-reviewed evidence actually shows about supplements and Lp(a), and how related inflammatory and metabolic biomarkers — including CRP, LDL particle number, and others — fit into a complete cardiovascular risk picture.
---
What Supplements Affect CRP?
C-reactive protein (CRP) is a sensitive inflammatory marker produced by the liver in response to systemic inflammation. Because Lp(a) itself promotes vascular inflammation, elevated CRP often accompanies high Lp(a) levels and compounds cardiovascular risk. Lowering CRP through targeted supplementation can reduce overall risk burden even when Lp(a) itself doesn't move substantially.
Omega-3 fatty acids (EPA/DHA) have among the strongest evidence for CRP reduction. A meta-analysis of 68 randomized controlled trials found that omega-3 supplementation significantly reduced CRP, with effects most pronounced at doses above 2 g/day of combined EPA and DHA (Calder et al., Nutrients, 2017; PMID: 28900017). Critically, omega-3s also appear to modestly lower Lp(a) levels in some studies — a dual action that makes them particularly relevant here.
Curcumin, the active compound in turmeric, has demonstrated meaningful CRP reductions in meta-analyses of clinical trials. One systematic review found curcumin supplementation lowered CRP by an average of 6.44 mg/L compared to placebo, with bioavailability-enhanced formulations (phospholipid complexes or piperine-combined forms) outperforming standard curcumin powder (Sahebkar et al., Critical Reviews in Food Science and Nutrition, 2016; PMID: 26507545).
Vitamin D3 influences CRP through its broad immunomodulatory effects. Multiple interventional trials show that correcting vitamin D deficiency — particularly when baseline 25(OH)D is below 30 ng/mL — reduces high-sensitivity CRP (hs-CRP). This is a key reason why Ones includes Vitamin D3 paired with K2 (MK-7) in personalized formulas: the combination ensures calcium is directed appropriately and that inflammatory pathways are not exacerbated by vitamin K insufficiency.
---
What Supplements Affect LDL Particle Number?
LDL particle number (LDL-P), measured via NMR lipoprofile or calculated from ApoB, is a stronger predictor of cardiovascular events than LDL cholesterol alone because it captures the atherogenic burden of small, dense LDL particles — which, like Lp(a), penetrate the arterial wall more easily than large, buoyant particles.
Niacin (Vitamin B3) is historically the most studied supplement for reducing both Lp(a) and LDL-P. High-dose niacin (1,000–3,000 mg/day, typically extended-release) has been shown to reduce Lp(a) by 20–30% in clinical trials, likely by suppressing hepatic apolipoprotein(a) synthesis. Niacin also shifts LDL particle distribution toward larger, less atherogenic particles (Goldberg et al., American Journal of Cardiology, 2000; PMID: 10760340). However, high-dose niacin requires medical supervision due to its side-effect profile, including flushing, hepatotoxicity risk at higher doses, and effects on blood glucose. This is not a supplement to self-prescribe.
Berberine has demonstrated meaningful reductions in LDL-P in a clinical setting and works through AMP-kinase activation and upregulation of LDL receptor expression — a mechanism complementary to statins. A meta-analysis including 27 randomized trials found berberine reduced total cholesterol by 0.61 mmol/L and LDL-C by 0.65 mmol/L compared to control (Pirillo & Catapano, Nutrition, Metabolism and Cardiovascular Diseases, 2015; PMID: 25861926). Its effect on Lp(a) specifically is less established, but improvements in overall lipid architecture make it a relevant consideration in a comprehensive cardiovascular supplement protocol.
Plant sterols and stanols, found in fortified foods and standalone supplements, compete with cholesterol absorption in the gut and reliably reduce LDL-C by 7–12% at intakes of 2 g/day. While their effect on Lp(a) is minimal, they support LDL particle reduction and are generally safe for long-term use.
---
What Supplements Affect ESR?
Erythrocyte sedimentation rate (ESR) is a non-specific inflammatory marker that rises with infection, autoimmune activity, and systemic inflammatory states. Like hs-CRP, elevated ESR in the context of high Lp(a) suggests compounding inflammatory burden on the vasculature.
Supplements that reduce CRP tend to overlap with those affecting ESR, since both reflect systemic inflammatory load. Omega-3s, curcumin, and vitamin D are the best-supported options. Additionally, magnesium plays an underappreciated role: magnesium deficiency is associated with elevated inflammatory markers including ESR, and supplementation with well-absorbed forms like magnesium glycinate has been shown to reduce inflammatory cytokine signaling in deficient individuals (Maier et al., Current Opinion in Clinical Nutrition & Metabolic Care, 2012; PMID: 22270037). Ones includes a Magnesium Complex system blend precisely because magnesium insufficiency is widespread — affecting an estimated 45% of Americans — and its downstream effects on inflammation are clinically meaningful.
The practical takeaway: ESR is rarely the primary target in a cardiovascular supplement strategy, but persistently elevated ESR alongside high Lp(a) should prompt investigation into underlying inflammatory drivers before defaulting to more aggressive lipid-lowering approaches.
---
What Supplements Affect A1C?
A1C (glycated hemoglobin) might seem unrelated to Lp(a) at first glance, but the connection is clinically important: insulin resistance and chronic hyperglycemia amplify cardiovascular risk in individuals with elevated Lp(a), and poor glycemic control is independently associated with increased small dense LDL particles — compounding atherogenic risk. Managing A1C is therefore a meaningful component of a holistic cardiovascular risk reduction strategy.
Berberine again earns mention here: its AMPK-activating mechanism mirrors that of metformin, and trials in type 2 diabetic populations show A1C reductions of 0.5–1.5% over 3 months at doses of 1,000–1,500 mg/day (Yin et al., Metabolism, 2008; PMID: 18471808). For individuals whose labs show both elevated Lp(a) and borderline A1C, this dual-action profile is compelling.
Chromium picolinate at 200–1,000 mcg/day has modest evidence for improving insulin sensitivity and reducing A1C in pre-diabetic and diabetic populations, though effect sizes are smaller than berberine. Alpha-lipoic acid (ALA) supports mitochondrial glucose metabolism and has demonstrated A1C reduction in several trials, though evidence quality is mixed.
For personalized formula users on Ones, A1C data drawn from blood work directly informs which metabolic-support ingredients are included — the AI doesn't just look at lipids in isolation. Elevated A1C alongside poor lipid markers triggers a more comprehensive metabolic protocol rather than a single-ingredient approach.
---
The Lp(a)-Specific Evidence: What Actually Moves the Number?
Let's return specifically to Lp(a). The honest evidence-based summary:
| Supplement | Effect on Lp(a) | Evidence Quality | Notes |
|---|---|---|---|
| Niacin (high-dose) | ↓ 20–30% | Moderate | Requires physician oversight |
| Omega-3 (EPA/DHA) | ↓ 5–10% (variable) | Moderate | Dose-dependent; concurrent CRP benefit |
| Vitamin C (high-dose) | Possible modest ↓ | Low–Moderate | Mechanistic rationale via Lp(a)-binding competition |
| Coenzyme Q10 | No direct effect | Low | Beneficial for overall cardiac function |
| Berberine | Minimal direct effect | Low | Beneficial for LDL-P and A1C |
| Statins | ↑ or neutral | Moderate | May slightly raise Lp(a) |
| PCSK9 inhibitors | ↓ 20–30% | High | Pharmaceutical, not supplement |
Vitamin C deserves its own note: there is a biological hypothesis — championed by Linus Pauling and later explored by others — that high-dose vitamin C competes with Lp(a) at binding sites in arterial walls. Pilot studies have shown some signal, and observational data suggest inverse associations between plasma ascorbate and Lp(a). However, large-scale RCT evidence is lacking. Ones includes its Immune-C and C Boost system blends, which provide clinically relevant doses of vitamin C alongside bioflavonoids for enhanced bioavailability — a meaningful addition to a cardiovascular-focused formula even if direct Lp(a) lowering remains unconfirmed.
CoQ10 (ubiquinol at 200mg) is another Ones ingredient worth flagging in this context: it doesn't lower Lp(a), but in individuals on statin therapy — where CoQ10 depletion is well-documented — restoring mitochondrial function in cardiac tissue provides meaningful protection against the oxidative stress that elevated Lp(a) exacerbates.
---
What This Means for Your Formula
Lp(a) management requires a multi-biomarker strategy. No single supplement will dramatically lower a genetically elevated Lp(a), but a well-constructed formula targeting the surrounding risk architecture — inflammation (CRP, ESR), LDL particle quality, and metabolic health (A1C) — can meaningfully shift overall cardiovascular risk.
For Ones users with high Lp(a) identified in their lab work, the AI analyzes the full biomarker picture before generating recommendations. A formula addressing elevated Lp(a) might include:
- Omega-3 (EPA/DHA) at therapeutic doses — the most evidence-backed option for both modest Lp(a) reduction and robust CRP lowering
- Vitamin D3 + K2 (MK-7) — to address the inflammatory amplification that vitamin D insufficiency causes, particularly relevant when hs-CRP is also elevated
- CoQ10/Ubiquinol at 200mg — if statin co-use is identified, or if mitochondrial and vascular oxidative stress markers are flagged
Additional ingredients from the Ones catalog — including components of the Heart Support and Endocrine Support system blends — may be incorporated depending on the full clinical picture drawn from wearable data and blood work history.
If you want to understand how your specific Lp(a) reading fits into your broader cardiovascular risk profile, understanding cardiovascular biomarkers and supplement timing is a useful next read. For those whose labs also show LDL pattern issues, optimizing LDL particle size through nutrition and supplementation covers the evidence in detail.
---
Key Takeaways
- Lp(a) is largely genetic and resistant to most interventions, but high-dose niacin and omega-3 fatty acids have the strongest evidence for modest reductions — niacin requires physician oversight due to side effects.
- CRP reduction is achievable with omega-3s (2+ g/day EPA/DHA), bioavailable curcumin, and correcting vitamin D deficiency — all of which reduce inflammatory burden that compounds Lp(a) risk.
- LDL particle number responds to berberine (via AMPK/LDL receptor upregulation), plant sterols, and omega-3s — improving overall lipid architecture even when Lp(a) itself doesn't move.
- A1C management matters for Lp(a)-positive individuals because insulin resistance amplifies atherogenic risk; berberine at 1,000–1,500 mg/day is the best-evidenced supplement option.
- ESR elevation alongside high Lp(a) signals compounding inflammatory load — magnesium, omega-3s, and curcumin address overlapping pathways.
- A personalized multi-biomarker approach — like the one Ones builds from actual lab data — is more effective than targeting Lp(a) in isolation with a single supplement.
---
This article is for educational purposes only. Consult a qualified healthcare provider before making changes to your supplement or medication regimen, particularly for cardiovascular risk management.